Publications by authors named "Michael James Naslund"
Objective: To examine utilization and costs of care for benign prostatic hyperplasia (BPH)-related services in a large cohort of commercially insured persons.
Methods: Pharmacy and medical claims data were obtained from 61 US healthcare plans. Men aged > or = 45 years who were newly diagnosed with BPH between January 2000 and March 2001 were identified.
Article Synopsis
- * Using a large national managed care database, researchers tracked costs and significant health events for diseases like hypertension, CAD, diabetes, and more for one year before and after treatment started.
- * Results showed that arrhythmias and CAD had the highest treatment costs, with a significant chance of clinical events in conditions like bursitis and enlarged prostate, indicating the need for better management of these diseases.
Article Synopsis
- Benign prostatic hyperplasia (BPH) is a common condition in men over 50, leading to complications that can significantly affect their health and wellbeing.
- This retrospective study analyzed patient data from a national database to evaluate the rates of acute urinary retention (AUR) and prostate surgeries after starting treatment with alpha blockers or 5-alpha reductase inhibitors.
- Results indicated that patients on 5-alpha reductase inhibitors had a lower likelihood of experiencing AUR and undergoing surgery compared to those on alpha blockers, although the differences in surgery rates were not statistically significant.